Scientists probe how lung cancer outsmarts key drugs
NCT ID NCT04222335
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find ways to prevent relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new treatments that prevent or overcome drug resistance in lung cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toulouse University Hospital
Toulouse, Occitanie, 31300, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could reveal how lung cancer evolves during treatment
- Early lung cancer drug combo trial halted after just 6 patients
- Blood test could guide who needs extra cancer therapy after lung surgery
- Tiny study probes risks of lung cancer combo therapy
- Blood markers may reveal which lung cancer patients stay Cancer-Free after treatment
- Lung cancer combo trial halted early – what we know